Dr. Prashant Jindal, Dr. Deepti Jindal, Dr. Rajesh Handa
Started at Panchkula. Legal entity: VITONNIX LTD; Company number: 08968626; Country of incorporation: United Kingdom; Registered office: 71 Francis Road, Edgbaston, Birmingham, England, B16 8SP; Incorporated: 31 March 2014; Status: Active; Company type: Private limited company; SIC: 86900 - Other human health activities; Previous legal name: ZESTBIOTICS LTD, from incorporation until 11 December 2015.
0.4
-
Vitonnix SubliSpray sublingual delivery platform, Multivitamin 3+ and Multivitamin 13+ sprays, Vitamin C, Vitamin D2, Vitamin B12, iron, folic acid and biotin sprays, Prega-1 and Prega-2 prenatal sprays, Energy Sublingual Spray, MacuZohm eye-health spray, Melatonin sleep spray, Glutathione skin-health spray, Veg Omega Spray
Founded: Panchkula; incorporated 31 March 2014.
Founder LinkedIn: Dr. Prashant Jindal - https://uk.linkedin.com/in/drprashantjindal
Founder LinkedIn: Dr. Deepti Jindal - https://uk.linkedin.com/in/dr-deepti-jindal-67988194
Funding: Not publicly disclosed.
Funding Amount: Bootstrapped
Acquisition: None publicly disclosed.
Partnership: Exclusive healthcare-products partnership with Tata 1mg announced in January 2024.
Retail Expansion: Boots UK announced a selected Vitonnix range for launch in Summer 2026.
Other important fact: Companies House lists Deepti Jindal as the active person with significant control owning 75% or more of the shares.
Sources:
- Official Vitonnix leadership page: https://vitonnix.in/pages/leadership
- Companies House company overview: https://find-and-update.company-information.service.gov.uk/company/08968626
- Official Vitonnix LinkedIn page: https://uk.linkedin.com/company/vitonnix
- Tata 1mg partnership report, Mint: https://www.livemint.com/companies/news/tata-1mg-vitonnix-jv-to-launch-products-11704733404986.html
- Boots UK launch announcement: https://ukreporter.co.uk/2026/04/18/boots-uk-launches-innovative-vitonnix-sublispray-range/
EBITDA: 0.05 Mil
Product Avg price: Rs 499
Obtained FSSAI Approval, MHRA approval pending.
Sold: 1 million bottles todate across 19000 pincodes. 32 SKUs.
Relationship between Veeshan Labs (Ops) and Veeshan Health (Mktg, IP).
| Attribute | Metric | Reference | Company Value |
|---|---|---|---|
| MOAT | Gross Margin Advantage over Competitor | 60-70% +/- Increment % | - |
| MOAT | Time to develop competing product | 2-5 Yrs Months | 24 Months |
| Patents and Technology | No. of Patents on Core Products | 2-5 No | - |
| Patents and Technology | Number of proprietary formulations | 10-15 Nos | - |
| Product Performance | LTV/CAC | 3X Ratio | - |
| Product Performance | Percentage of SKUs in Direct Search | 35% % | - |
| Product Performance | Repeat Purchase Rate | >40% Repeats/Frequency | - |
| Scientific IP | Acclaimed and completed human clinical studies | 1 per year, 5-10 Nos | - |
| Scientific IP | Bioavailability | 1-20% % | - |
| Scientific IP | Number of SKUs backed by clinical evidence | 5-10 Nos | - |